[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Corp (ADPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,053,365
  • Shares Outstanding, K 160,044
  • Annual Sales, $ 276,980 K
  • Annual Income, $ -59,500 K
  • EBIT $ -45 M
  • EBITDA $ -30 M
  • 60-Month Beta 2.16
  • Price/Sales 7.62
  • Price/Cash Flow N/A
  • Price/Book 9.39

Options Overview Details

View History
  • Implied Volatility 133.02% (+14.11%)
  • Historical Volatility 65.37%
  • IV Percentile 76%
  • IV Rank 36.95%
  • IV High 260.99% on 02/17/26
  • IV Low 58.02% on 06/13/25
  • Expected Move (DTE 32) 1.59 (12.39%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 33
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 990
  • Open Int (30-Day) 820
  • Expected Range 11.24 to 14.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 4
  • High Estimate $-0.13
  • Low Estimate $-0.15
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.81 +0.16%
on 05/15/26
15.15 -15.31%
on 04/21/26
-1.70 (-11.70%)
since 04/15/26
3-Month
12.00 +6.92%
on 03/12/26
16.95 -24.31%
on 03/04/26
-3.21 (-20.01%)
since 02/13/26
52-Week
8.50 +50.94%
on 05/23/25
20.76 -38.20%
on 11/25/25
+3.92 (+44.00%)
since 05/15/25

Most Recent Stories

More News
Adaptive Biotechnologies: Q1 Earnings Snapshot

Adaptive Biotechnologies: Q1 Earnings Snapshot

ADPT : 12.83 (-2.66%)
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

ADPT : 12.83 (-2.66%)
Adaptive Biotechnologies Reports Tomorrow With MRD Segment Under Microscope

Barchart Research What to Expect from ADPT Earnings ADPT Generated May 4, 2026 Current Price $14.50 EPS Estimate $$-0.16 Consensus Rating Strong Buy Average Move 8.43% Adaptive Biotechnologies Reports...

ADPT : 12.83 (-2.66%)
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 12.83 (-2.66%)
Adaptive Biotechnologies: Q4 Earnings Snapshot

Adaptive Biotechnologies: Q4 Earnings Snapshot

ADPT : 12.83 (-2.66%)
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

ADPT : 12.83 (-2.66%)
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 12.83 (-2.66%)
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 12.83 (-2.66%)
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 12.83 (-2.66%)
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

ADPT : 12.83 (-2.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 13.39
2nd Resistance Point 13.27
1st Resistance Point 13.05
Last Price 12.83
1st Support Level 12.71
2nd Support Level 12.59
3rd Support Level 12.37

See More

52-Week High 20.76
Fibonacci 61.8% 16.08
Fibonacci 50% 14.63
Fibonacci 38.2% 13.18
Last Price 12.83
52-Week Low 8.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.